Showing results (81-90 of 125) with videos related to

Sort By:
Pageof 13
Journal of Medicinal Chemistry|July 9, 2015
Novel Azido-Iodo Photoaffinity Ligands for the Human Serotonin Transporter Based on the Selective Serotonin Reuptake Inhibitor (S)-CitalopramVivek Kumar, Nageswari Yarravarapu, David J Lapinsky, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 11, 2011
High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral TherapyKristin E Mondy, John Gottdiener, E Turner Overton, et al.
American Journal of Epidemiology|December 17, 2008
The study to understand the natural history of HIV and AIDS in the era of effective therapy (SUN Study)Claudia Vellozzi, John T Brooks, Timothy J Bush, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 6, 2006
A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in IndiaHeather E Vezina, Keith Henry, G D Ravindran, et al.
The Journal of Infectious Diseases|December 7, 2017
Prevalence, Incidence, and Clearance of Anal High-Risk Human Papillomavirus Infection Among HIV-Infected Men in the SUN StudyPragna Patel, Tim Bush, Erna Milunka Kojic, et al.
AIDS Care|February 5, 2011
Factors associated with non-adherence to antiretroviral therapy in the SUN studyMelanie Kyser, Kate Buchacz, Timothy J Bush, et al.
The Lancet. Infectious Diseases|June 9, 2014
Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week results of a randomised, open-label, phase 3b non-inferiority trialAnton Pozniak, Martin Markowitz, Anthony Mills, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 23, 2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 resultsJürgen K Rockstroh, Edwin DeJesus, Keith Henry, et al.
Sexually Transmitted Diseases|December 21, 2011
Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventionsKenneth H Mayer, Timothy Bush, Keith Henry, et al.
Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialEdwin DeJesus, Jürgen K Rockstroh, Keith Henry, et al.
Pageof 13